Enox Biopharma, Inc. Will Be Granted a Patent for the Delivery of Therapeutic Agents From Within Medical Devices

VANCOUVER, British Columbia, June 13, 2011 /PRNewswire/ -- Enox Biopharma, Inc., a leader in the development of innovative solutions for infections associated with medical devices, today announced that it has received notification from the European Patent Office that its patent application entitled "Device and Method for Administering Therapeutic Agents" has been approved and a patent will be granted.

Enox acquired this patent from its Swedish Inventors, Dr. Jon Lundberg and Dr. Eddie Wietzberg. The patent covers the release of low molecular weight antimicrobial agents, and of specific interest to Enox's portfolio is the release of nitric oxide.  Nitric oxide is well recognized as an ideal antimicrobial agent that is highly effective yet free from the drug resistance issues that have resulted from excessive antibiotic use. The unstable nature of nitric oxide has prevented its clinical use to reduce infections emanating from medical devices. Enox Biopharma has already protected the dosing and release of polymers with nitric oxide which is sequestered in the polymer in a stable state. The new patent expands Enox's unique intellectual property portfolio with regard to the release of nitric oxide from medical devices.

"Hospital acquired infections are a significant cause of death in every country in the world," noted Enox's CEO, John Rewcastle, Ph.D. "Their financial drag impedes the ability of healthcare systems to provide optimal, or in some cases, even effective care. This strategic patent allows Enox to proceed full speed with creating antimicrobial medical devices that emit nitric oxide as it solidifies Enox as the only company that can create such devices."

About Enox Biopharma, Inc.

Enox Biopharma, Inc. is an emerging biotechnology company with proprietary methods to sequester nitric oxide (NO) into polymers. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. NO is also an effective vasodilator which can lead to accelerated wound healing. Enox's device technology is applicable to any indwelling polymer medical device including, but not limited to catheters, endotracheal tubes and central venous catheters. Infections from these devices, which are often not reimbursed by Medicare, represent a massive financial burden to healthcare systems worldwide.

For more information, please contact:

John C. Rewcastle, Ph.D, CEO or
Itamar David, CFO
Enox Biopharma, Inc.
604.637.9744 phone

888.224.7259 fax
[email protected]
www.enoxbiopharma.com

SOURCE Enox Biopharma, Inc.